News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase III
bluebird bio (BLUE) Announces Topline Interim Clinical Data From Starbeam Study Of Lenti-D Drug Product In Cerebral Adrenoleukodystrophy (CALD) 6/27/2017
Kitov (KTOV) Updates On KIT-302 New Drug Application 6/27/2017
Alder Biopharma's Migraine Med Hits Goals In Late-Stage Trial 6/27/2017
Teva (TEVA), Xenon Pharma's Nerve Pain Med Fails To Meet All Endpoints In Phase III Study 6/27/2017
Merck & Co. (MRK)'s Midas Touch Continues as Heart Drug Succeeds Where Pfizer (PFE), Eli Lilly (LLY) and Roche (RHHBY)'s Failed 6/27/2017
Strongbridge Biopharma Completes Target Enrollment Of 90 Patients In The Phase III SONICS Study Evaluating RECORLEV (Levoketoconazole) In Endogenous Cushing’s Syndrome 6/27/2017
Will AbbVie (ABBV) Outsmart Biosimilars, And Can Clovis Oncology (CLVS) Win The PARP Race? 6/27/2017
A Look at the Deaths That Plagued Juno (JUNO) and Kite Pharma (KITE)'s CAR-T Trials 6/27/2017
Investors Relieved as Seattle Genetics (SGEN) Pulls Out Win for Phase III Lymphoma Trial 6/26/2017
Genentech (RHHBY)'s Hemophilia Blockbuster Contender Hits Phase III Goals, But Questions Remain 6/26/2017
bluebird bio (BLUE) Touts Impressive Data From Late-Stage Gene Therapy Study 6/26/2017
Bristol-Myers Squibb (BMY) Release: Four-Year Follow-Up With Empliciti (Elotuzumab) Plus Lenalidomide/Dexamethasone (Eld) In Patients With Advanced Multiple Myeloma Shows Long-Term Efficacy In ELOQUENT-2 Trial 6/26/2017
The New England Journal of Medicine Publishes Full Analysis Of Rydapt (Midostaurin) Phase III RATIFY Trial In Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML) 6/26/2017
Genentech (RHHBY)’s Emicizumab Showed Positive Results In Phase III Studies (HAVEN 1 And HAVEN 2) In Hemophilia A With Inhibitors 6/26/2017
Chugai Pharma''s Bispecific Antibody Emicizumab To Present Results Of Two Pivotal Phase III Studies At ISTH 6/26/2017
European Hematology Association: Early Metabolic Response Determination By FDG-PET Allows Substantial Reduction Of Chemotherapy And Its Toxicity In Patients With Advanced Stage Hodgkin Lymphoma: The GHSG HD18 Study 6/26/2017
Onconova (ONTX) Presents Rigosertib Data At The 22nd Congress Of The European Hematology Association In Madrid 6/26/2017
Lipocine (LPCN) Announces Submission Of SPA On LPCN 1107, An Oral Alternative For The Prevention Of Preterm Birth 6/26/2017
Mithra Pharmaceuticals Release: Estelle Phase IIb Results On Well-Being And Body Weight Published In Leading Peer-Reviewed Journal 6/26/2017
OSE Immunotherapeutics Announces Temporary Pause Of Patient Accrual While Continuing Treatment For Patients Already Enrolled In Phase III Clinical Trial Of Tedopi In Advanced Lung Cancer 6/26/2017
Amgen (AMGN) Goes on the Defensive When Critics Call Its Pipeline a Dud 6/23/2017
New Data At EAN Show Genentech (RHHBY)’s Ocrevus (Ocrelizumab) Significantly Reduced Multiple Measures Of Disease Progression In Relapsing And Primary Progressive Multiple Sclerosis 6/23/2017
bluebird bio (BLUE) Announces Early Data From Phase III Northstar-2 (HGB-207) Study Of LentiGlobin Drug Product At European Hematology Association Annual Meeting 6/23/2017
Top 3 Biotechs With Potential Blockbusters In The Late-Stage Pipeline 6/22/2017
DelMar Pharma Receives Institutional Review Board Approval For Pivotal Phase III Clinical Trial Of VAL-083 In Refractory GBM 6/22/2017
Indivior Presents Results From The Phase III Pivotal Study Of RBP-6000 Buprenorphine Monthly Depot For The Treatment Of Opioid Use Disorder 6/22/2017
DURECT (DRRX) Completes Enrollment In PERSIST, Phase III Trial For POSIMIR 6/22/2017
Minerva Neurosciences (NERV) Announces Completion Of Bridging Study To Select Improved Formulation Of MIN-101 For Use In Phase III Trial For The Treatment Of Negative Symptoms In Patients With Schizophrenia 6/22/2017
Alzheon Publishes New Analyses Showing Clinical Benefit Of Tramiprosate In APOE4/4 Homozygous Patients With Mild Alzheimer’s Disease; Clinical Effects Suggest Disease Modification And Align With Beta Amyloid Oligomer Formation 6/22/2017
Surprise: Novartis AG (NVS) Heart Drug Wows in Late-Stage Study 6/22/2017
Zogenix (ZGNX) Receives Orphan Drug Designation From FDA For ZX008 In Treatment Of Lennox Gastaut Syndrome 6/22/2017
Advicenne To Present Preliminary Phase III Clinical Data On ADV7103 At The Upcoming European Society Of Pediatric Nephrology’s Annual Meeting 6/22/2017
Money Problems Push SoCal's ImmunoCellular (IMUC) To Suspend Trial, Seek Strategic Alternatives 6/21/2017
Novartis AG (NVS)'s Next-Generation Eye Drug Works With Fewer Injections Than Rivals 6/21/2017
BIO2017: Eli Lilly (LLY) Clinical Development Head Looks to Innovate, Continue Alzheimer’s Research 6/21/2017
Vanda (VNDA): Several Catalysts Coming Up 6/21/2017
Cara Therapeutics (CARA) Reports Continuation Of Phase III Trial Of I.V. CR845 In Postoperative Pain Following Interim Assessment 6/21/2017
Mithra Pharmaceuticals Completes Recruitment For Additional Estelle Safety Study 6/21/2017
Positive Phase III For GlaxoSmithKline (GSK)'s Shingles Vaccine Shingrix With Agenus (AGEN)' QS-21 Stimulon Immune Adjuvant 6/21/2017
GlaxoSmithKline (GSK) Presents Positive Results From Phase III Revaccination Study Of Its Candidate Shingles Vaccine Shingrix At CDC's Advisory Meeting 6/21/2017
Amgen (AMGN) To Present New Data At 22nd Congress Of The European Hematology Association 6/21/2017
More Deaths Lead Seattle Genetics (SGEN) to Discontinue Phase III Leukemia Study 6/21/2017
Clovis Oncology (CLVS) Stock Soars as Ovarian Cancer Trial Dazzles 6/21/2017
Inovio Pharma (INO) CEO Forging Multiple Deals, Expanding Pipeline and Adding 100 New Jobs 6/20/2017
How Upcoming Mystic Data Will Be AstraZeneca PLC (AZN) CEO's Biggest Test 6/20/2017
AVEO Oncology (AVEO) Announces Pivotal Phase III TIVO-3 Study Of Tivozanib In Renal Cell Carcinoma Reaches Enrollment Target 6/20/2017
Immune Pharma Announces Initiation Of Enrollment In Clinical Trial With Ceplene/ Low-Dose IL-2 In Chronic Myelomonocytic Leukemia (CMML) 6/20/2017
Helsinn Group Announces Upcoming Presentation Of Phase III Data In NEPA (Netupitant/Palonestron) At MASCC/ISOO Congress In Washington DC 6/20/2017
Galapagos (GLPG.BR)' R&D Update 2017: Rapidly Advancing Our Product Candidates 6/20/2017
Lipocine (LPCN) Validates “No Titration” Dosing Regimen With Positive Topline Efficacy Results For LPCN 1021, Oral Testosterone Candidate 6/20/2017
New Data Reveals This New York Biotech's Pipeline Could be a Game Changer 6/19/2017
While Amgen (AMGN)-Size Biotechs Run Into Trouble, These Are The Biotechs With The Most Promising Pipelines 6/19/2017
ASIT Biotech Discloses Comments From The Paul Ehrlich Institute And Presents Detailed Results On The Phase III Clinical Study Of Gp-ASIT + At EAACI 2017 6/19/2017
VBI Vaccines Reports Positive Outcome From Phase III Pre-IND Discussions With The FDA For Hepatitis B Vaccine, Sci-B-Vac 6/19/2017
RedHill Biopharma (RDHL) To Host Conference Call On Successful Phase III Top-Line Results With BEKINDA For Acute Gastroenteritis 6/19/2017
Janssen-Cilag AG Release: Three-Year Follow-Up Data Showed Patients Achieved Four-Fold Progression-Free Survival Benefit With Single Agent Imbruvica (Ibrutinib) Vs Temsirolimus At First Relapse In Mantle Cell Lymphoma 6/19/2017
Why Drug Giants Like Merck & Co. (MRK) and AstraZeneca PLC (AZN) Scientists are Looking in the Toilet for New Cancer Treatments 6/16/2017
Why This Overlooked New Jersey Biotech Could be an Orphan Underdog 6/16/2017
EULAR 2017: Eli Lilly (LLY)'s Taltz (ixekizumab) Demonstrated No Progression Or Minimal Progression Of Radiographic Disease In Patients With Psoriatic Arthritis Through 52 Weeks 6/16/2017
Eli Lilly (LLY) Release: New Safety And Long-Term Efficacy Data From Baricitinib Clinical Trials In Patients With Moderate-To-Severe Rheumatoid Arthritis Presented At EULAR 2017 6/16/2017
DelMar Pharma Presents Poster Of Clinical Research With VAL-083 In Patients With Chemo-Resistant Glioblastoma ("GBM") At SNO's Pediatric Neuro-Oncology Basic And Translational Research Conference 6/16/2017
TG Therapeutics (TGTX) Recaps Positive Data From The Phase III GENUINE Trial And Data From The Triple Combination Of TG-1101, TGR-1202, And Ibrutinib At The 14th International Conference On Malignant Lymphoma 6/16/2017
Xeris Pharma Announces New Results From Ready-To-Use Liquid Glucagon Clinical Development Program 6/16/2017
Bavarian Nordic (BAVA.CO) Provides Update On Anticipated Timing Of PROSPECT Study 6/16/2017
How Your Daily Cup Of Coffee Could Be Saving Your Liver, Journal of Hepatology Reveals 6/15/2017
Opko Health (OPK) Provides Update To Topline Data Of Phase III Clinical Study Of Hgh-CTP In Growth Hormone Deficient Adults 6/15/2017
LEO Pharma Starts Phase III Clinical Study For Tralokinumab In Atopic Dermatitis 6/15/2017
RedHill Biopharma (RDHL) Announces Confirmatory Phase III Study Initiated With RHB-105 (TALICIA) For H. Pylori Infection 6/15/2017
Braeburn Pharma And Camurus Announce Presentations Of Pivotal Clinical Study Data Of Long-Acting Buprenorphine 6/15/2017
EULAR 2017: Eli Lilly (LLY)'s Taltz (Ixekizumab) Demonstrated Significant Improvements In Disease Signs And Symptoms At 24 Weeks Among Patients With Active Psoriatic Arthritis Who Had Prior Inadequate Response Or Intolerance To TNF Inhibitors 6/15/2017
Sirnaomics Advances Leading siRNA Therapeutic Candidate, STP705, For Treatment Of Liver Fibrosis 6/15/2017
RedHill Biopharma (RDHL) Announces Successful Phase III Top-Line Results With BEKINDA For Acute Gastroenteritis 6/15/2017
Achelios Therapeutics Concludes Successful Type C Meeting With FDA Regarding Its Lead Product, TOPOFEN, For Prevention And Treatment Of Migraine 6/14/2017
Why Celgene (CELG) Gets No R-E-S-P-E-C-T, But Should 6/14/2017
Janssen Pharmaceutical Release: New Phase III Data Show Anti-TNF Alpha SIMPONI ARIA (golimumab) Significantly Improved Arthritis And Skin Manifestations In Patients With Active Psoriatic Arthritis 6/14/2017
Bristol-Myers Squibb (BMY) To Present New Research Related To The Treatment Of Rheumatoid Arthritis Patients With Highly Active, Progressive Disease At The Annual European Congress Of Rheumatology (EULAR 2017) 6/14/2017
Boehringer Ingelheim Presents Phase III Results Demonstrating Clinical Equivalence Of Adalimumab Biosimilar Candidate To HUMIRA 6/14/2017
How A Celgene (CELG)-Partnered Drug Trial Could Save Struggling Acceleron Pharma 6/14/2017
Janssen-Cilag International NV (JNJ) Presents Long Term Phase III Efficacy And Safety Data Of Sirukumab In Rheumatoid Arthritis Patients Who Had An Inadequate Response And/Or Who Were Intolerant To Anti-TNFs 6/14/2017
RedHill Biopharma (RDHL) Announces Successful Phase III Top-Line Results With BEKINDA For Acute Gastroenteritis 6/14/2017
Deaths Force Merck & Co. (MRK) to Halt Enrollment for Blood Cancer Studies 6/14/2017
SoCal's Regulus (RGLS) Sinks After AstraZeneca PLC (AZN) Bails on Lead NASH Drug 6/13/2017
FDA Calls Omeros (OMER)' Kidney Disorder Drug a Breakthrough 6/13/2017
Adamas Pharma (ADMS) Announces Publication Of ADS-5102 Phase III EASE LID Clinical Trial In JAMA Neurology 6/13/2017
Research Published In Scientific Reports Uses State-Of-The-Art CRISPR Technology To Validate Relevance Of The Dimerix Receptor-HIT Technology In Real Time 6/13/2017
TiGenix Launches Global Phase III Trial For Cx601 6/13/2017
Janssen Pharmaceutical Release: INVOKANA (canagliflozin) Significantly Reduces The Combined Risk Of Cardiovascular Death, Myocardial Infarction And Stroke In The CANVAS Program 6/13/2017
Janssen-Cilag International NV (JNJ) Release: INVOKANA (Canagliflozin) Significantly Reduces The Combined Risk Of Cardiovascular Death, Myocardial Infarction, And Stroke In The CANVAS Programme 6/13/2017
Merck & Co. (MRK) Provides Update On Multiple Myeloma Studies KEYNOTE-183 And 185 Of KEYTRUDA (Pembrolizumab) In Combination With Other Therapies 6/13/2017
Aimmune (AIMT) Reports On Up-Dosing In Its Ongoing Phase III PALISADE Trial Of AR101 For Peanut Allergy 6/13/2017
Agendia BV Release: Three New Studies Presented At ASCO Annual Meeting Demonstrate Benefits Of Mammaprint In Aiding Individualized Treatment Management For Early-Stage Breast Cancer Patients 6/13/2017
Pfizer (PFE) And Eli Lilly (LLY) Receive FDA Fast Track Designation For Tanezumab 6/13/2017
pSivida (PSDV)'s Eye Drug/Device Hits Goals In Second Late-Stage Study 6/13/2017
Merck & Co. (MRK), Pfizer (PFE)'s New Diabetes Med Met Primary Endpoints In Two Phase III Studies 6/12/2017
Foamix Pharma (FOMX) Announces Dosing Of First Patient In Phase III Rosacea Clinical Trials For FMX103 Minocycline Foam 1.5% 6/12/2017
AstraZeneca PLC (AZN) Release: Astrazeneca Presents New Data Underpinning Safety Profile And Real-World CV Outcomes Of Farxiga At American Diabetes Association 2017 6/12/2017
Lexicon Pharma (LXRX) Release: Sotagliflozin Data From Pivotal inTandem1 And inTandem2 Studies In Patients With Type 1 Diabetes Presented At American Diabetes Association 2017 6/12/2017
Novo Nordisk A/S (NVO) Release: Xultophy 100/3.6 Demonstrated Similar A1C Reductions With Significantly Lower Rates Of Hypoglycemia And A Decrease In Weight Vs Basal-Bolus Therapy 6/12/2017
Vertex (VRTX) Announces Nine Presentations Of Data On ORKAMBI (Lumacaftor/Ivacaftor) And KALYDECO (Ivacaftor) At The European Cystic Fibrosis Society (ECFS) Conference 6/12/2017
Seres Therapeutics (MCRB) Initiates SER-109 Phase III Study In Patients Withmultiply Recurrent C. Difficile Infection 6/12/2017
Merck & Co. (MRK) And Pfizer (PFE) Announce That Investigational SGLT-2 Inhibitor Ertugliflozin Met Primary Endpoint In Two Phase III Studies 6/12/2017
Regeneron (REGN) And Sanofi (SNY) Announce Positive Results From First Dedicated Studies Evaluating Praluent (Alirocumab) In Individuals With Diabetes And Hypercholesterolemia 6/12/2017
Eli Lilly (LLY)'s Galcanezumab Significantly Reduces Number Of Migraine Headache Days For Patients With Migraine: New Results Presented At AHS 6/12/2017
Alkermes (ALKS) Announces Initiation Of Study 217 For ALKS 5461 For Treatment Of Major Depressive Disorder 6/12/2017
Independent Data Monitoring Committee Recommends Continuation Of Cancer Prevention Pharma’ Phase III Trial For Familial Adenomatous Polyposis Patients 6/12/2017
Mateon Therapeutics (MATN) Provides Update On Its Clinical Trial Programs And Milestones 6/12/2017
Tonix Pharma (TNXP) To Present An Update Of FDA Designated Breakthrough Therapy-TNX-102 SL For PTSD At The 2017 Marcum Microcap Conference 6/12/2017
Actinium (ATNM.OB) To Host Webinar On June 12th To Update On Pivotal Phase III SIERRA Clinical Trial For Iomab-B 6/12/2017
Zealand Pharma  (ZEAL.CO) Release: New Analysis Shows Soliqua 100/33 Lowered HbA1c By More Than 2% In Patients With Screening Levels Greater Than 9% 6/12/2017
Lexicon Pharma (LXRX) Surges On Positive Phase III For New Diabetes Drug 6/9/2017
Adamas Pharma (ADMS) Presents Expanded Analysis From The ADS-5102 Open-Label Study Showing Tolerability And Durability Out To 88 Weeks 6/9/2017
Vertex (VRTX) Announces Nine Presentations Of Data On ORKAMBI (Lumacaftor/Ivacaftor) And KALYDECO (Ivacaftor) At The European Cystic Fibrosis Society (ECFS) Conference 6/9/2017
Medivir (MVRBF) - Enrollment Completed In The MIV-711 Osteoarthritis Extension Study And Data Monitoring Committee Recommendation To "Go Ahead" 6/9/2017
Amgen (AMGN) Presents Erenumab Data At The 59th Annual Scientific Meeting of the American Headache Society 6/9/2017
Novartis AG (NVS) Presents Data Demonstrating Efficacy Of AMG 334 (Erenumab) In Migraine Prevention At The American Headache Society Annual Meeting 6/9/2017
PharmaCyte (PMCB) Updates Shareholders On ASCO Presentation To Oncologists 6/9/2017
Astellas (ALPMY) And Pfizer (PFE) Announce Amendment To Clinical Research Protocol For Phase III PROSPER Trial Of Enzalutamide In Patients With Non-Metastatic Castration-Resistant Prostate Cancer 6/9/2017
Tiny Bay Area Biotech Wants to Rattle the Billion-Dollar Injectable Drug Markets With a Single Pill 6/8/2017
Bristol-Myers Squibb (BMY) Loses $4.3 Billion in Market Value After ASCO Update 6/8/2017
Can-Fite BioPharma (CFBI) Concludes Successful Clinical Investigator Meeting For Its Acrobat Phase III Trial Of Piclidenoson In The Treatment Of Rheumatoid Arthritis 6/8/2017
Alkermes (ALKS) Announces Initiation Of Phase III Study Of ALKS 3831 In Young Adult Patients 6/8/2017
Alder Biopharma To Present Migraine Prevention Data For Eptinezumab At 59th Annual Scientific Meeting Of The American Headache Society 6/8/2017
Actelion (ALIOF.PK) Reports Good And Bad News For Phase III CDAD Trials 6/8/2017
Inovio Pharma (INO) Begins Phase III Clinical Trial Of VGX-3100 For The Treatment Of HPV-Related Cervical Pre-Cancer 6/8/2017
Actinium (ATNM.OB) Highlights Presence At Upcoming Society Of Nuclear Medicine And Molecular Imaging Annual Meeting 6/8/2017
Merz Neurosciences Announces Positive Phase III Results Of Xeomin (Incobotulinumtoxina) For Sialorrhea At 2017 MDS Meeting 6/8/2017
Why Johnson & Johnson (JNJ)'s New Prostate Cancer Drug Could Spell Trouble For Pfizer (PFE) 6/7/2017
Jazz Pharma (JAZZ) Presents Data For The Phase III TONES 2 Study Of JZP-110 In Patients With Excessive Sleepiness Associated With Narcolepsy 6/7/2017
Mallinckrodt (MNK) Enrolls First Patient In Phase III Trial Of StrataGraft Regenerative Skin Tissue 6/7/2017
Rebiotix Data Presented At ASM Microbe 2017 Show RBX2660 Treated Patients' Clinical Success Correlates With Improved Microbiome Diversity 6/7/2017
Jazz Pharma (JAZZ) Presents JZP-110 Data In Patients With Excessive Sleepiness Associated With Obstructive Sleep Apnea 6/7/2017
Takeda (TKPYY) And Seattle Genetics (SGEN) Announce Lancet Publication Of Phase III Alcanza Clinical Trial Data Of Adcetris (Brentuximab Vedotin) For CD30-Positive Cutaneous T-Cell Lymphoma 6/7/2017
Teva (TEVA)'s Fremanezumab Meets All Primary & Secondary Endpoints Across Both Monthly And Quarterly Dosing Regimens 6/7/2017
AbbVie (ABBV)'s RA Drug Meets All Primary And Secondary Endpoints In Phase III Study 6/7/2017
Soin Neuroscience Files An Orphan Drug Application To Treat Systemic Sclerosis 6/7/2017
Amgen (AMGN) And Allergan (AGN) Announce FDA Advisory Committee Meeting To Review ABP 215, A Biosimilar Candidate To Bevacizumab 6/7/2017
Acorda (ACOR) Jumps as Parkinson’s Drug Performs Well in Late-Stage Study 6/6/2017
EMA Accepts Design Of NeuroDerm (NDRM)'s ND0612 Phase III Indigo Efficacy Trial 6/6/2017
Data Of Chugai Pharma's Alecensa Presented At ASCO On Global Phase III ALEX Study 6/6/2017
Hutchison China MediTech (Chi-Med) Highlights Phase III Fruquintinib Data In Oral Presentation At ASCO 6/6/2017
Acorda (ACOR) Release: CVT-301 Phase III Data Showed Significantly Improved Motor Function During OFF Periods In Parkinson’s Disease 6/6/2017
Pfizer (PFE) Receives FDA Fast Track Designation For Tafamidis For Transthyretin Cardiomyopathy 6/6/2017
MorphoSys AG Starts Phase III Trial Of MOR208 Plus Bendamustine In Patients With Relapsed Or Refractory DLBCL 6/6/2017
AstraZeneca PLC (AZN) Release: LYNPARZA (Olaparib) Significantly Reduces The Risk Of Disease Worsening Or Death In Patients With BRCA-Mutated Metastatic Breast Cancer 6/6/2017
Puma Biotech (PBYI) Gets A Leg Up As Genentech (RHHBY) Suffers Blow Over Breast Cancer Combo Therapy 6/5/2017
Elated Bristol-Myers Squibb (BMY), Seattle Genetics (SGEN) Rewrite Agreement to Push Promising Drug Combo Into Phase III 6/5/2017
CEL-SCI (CVM) Submits FDA Response For Its Phase III Head And Neck Cancer Trial 6/5/2017
Avivagen Provides Business Updates 6/5/2017
Janssen-Cilag International NV (JNJ) Release: Abiraterone Acetate Provided Significant Clinical Benefit In Patients With High-Risk Metastatic Hormone-Naïve Prostate Cancer (mHNPC), Improving Overall Survival And Radiographic Progression-Free Survival 6/5/2017
Updated Data From KEYNOTE-024 Show Continued Overall Survival Benefit Of Merck & Co. (MRK)’s KEYTRUDA (Pembrolizumab) Compared To Chemotherapy In The First-Line Treatment Of Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) With High Levels Of PD-L1 6/5/2017
New Microbiology Data Reinforce Activity Of Paratek Pharma (PRTK)’s Omadacycline Against Pathogens Of Importance In Respiratory, Skin And Urinary Tract Infections 6/5/2017
Dendreon (DNDN) Announces New Findings Demonstrating Durable And Robust Killer T-Cell Response With PROVENGE 6/5/2017
Eisai Inc. (ESALF.PK) Release: Lenvatinib Demonstrates Positive Results Vs Sorafenib Across All Endpoints In First-Line Phase III Non-Inferiority Trial Of Unresectable Hepatocellular Carcinoma (uHCC) 6/5/2017
Eli Lilly (LLY) Builds Upon Body Of Data For Abemaciclib With Phase III MONARCH 2 Data Demonstrating Superior Progression-Free Survival In Advanced Breast Cancer 6/5/2017
Amgen (AMGN) Presents New Data From Phase III XGEVA (Denosumab) Study In Patients With Multiple Myeloma At ASCO 2017 6/5/2017
APHINITY Study Shows Genentech (RHHBY)’s Perjeta-Based Regimen Reduced The Risk Of Invasive Cancer Returning Compared To Herceptin And Chemotherapy In HER2-Positive Early Breast Cancer 6/5/2017
AbbVie (ABBV) Release: Long-Term IMBRUVICA (ibrutinib) Efficacy And Safety Data At ASCO 2017 Show Sustained Survival Rates In Up To Four Years In Previously-Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Patients, Including Those With High-Risk Disease 6/5/2017
Phase III Study Showed Genentech (RHHBY)’s Alecensa (Alectinib) Reduced The Risk Of Disease Progression Or Death By More Than Half Versus Crizotinib As First-Line Treatment In A Specific Type Of Lung Cancer 6/5/2017
Novoteris, LLC Receives FDA And Health Canada Clearance To Start A Phase II Clinical Trial Of Its Thiolanox Nitric Oxide For The Treatment Of Cystic Fibrosis 6/5/2017
Janssen-Cilag International NV (JNJ) Release: Darzalex (Daratumumab) Combination Therapy Improved Clinical Outcomes Regardless Of Cytogenetic Risk For Previously-Treated Patients With Multiple Myeloma 6/5/2017
Janssen R&D Release: Data At ASCO Show Consistent Progression-Free Survival Benefit In Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients Treated With Ibrutinib, Including Those With High-Risk Disease, With Up To Four Years Of Follow-Up 6/5/2017
AbbVie (ABBV) Release: New Data Presented At ASCO 2017 Finds IMBRUVICA (Ibrutinib) May Offer A More Targeted Approach To Chronic Lymphocytic Leukemia (CLL) Treatment Than Chemotherapy Agent Chlorambucil In Treatment-Naïve Patients 6/5/2017
With More than One-Year Follow-Up, Merck & Co. (MRK)’s KEYTRUDA (Pembrolizumab) Shows Continued Overall Survival Benefit Over Chemotherapy As Second-Line Treatment For Advanced Urothelial Carcinoma Patients Post-Platinum Failure 6/5/2017
Bristol-Myers Squibb (BMY) New Data Evaluating The Safety And Preliminary Relapse-Free Survival Of Adjuvant Yervoy (Ipilimumab) 3 Mg/Kg And 10 Mg/Kg In Resected High-Risk Melanoma Patients Presented At ASCO 6/5/2017
AstraZeneca PLC (AZN) Release: LYNPARZA (Olaparib) Significantly Reduces The Risk Of Disease Worsening Or Death In Patients With BRCA-Mutated Metastatic Breast Cancer 6/5/2017
Celltrion Healthcare (068270.KQ) Biosimilar Trastuzumab Candidate, CT-P6, Shown To Be Similar In Efficacy And Safety To The Reference Trastuzumab 6/5/2017
Vital Therapies (VTL) Announces Characteristics Of Early Subjects In VTL-308 Pivotal Study Of ELAD System In Severe Alcoholic Hepatitis 6/5/2017
Orbus Therapeutics Announces ASCO Study Design Presentation Of Pivotal Clinical Trial In Patients With Late-Stage Brain Cancer 6/5/2017
Janssen-Cilag International NV (JNJ) Release: Abiraterone Acetate Plus Prednisone Provided Significant Clinical Benefit In Patients With High-Risk Metastatic Hormone-Naïve Prostate Cancer (Mhnpc), Improving Overall Survival And Radiographic Progression-Free Survival 6/5/2017
Peregrine (PPHM) Presents Preliminary Correlative Analysis Of PD-L1 Expression From SUNRISE Trial At ASCO 2017 6/5/2017
Novartis AG (NVS) Lays Out R&D Game Plan at Meet and Greet With 30 Execs in Boston 6/2/2017
Janssen Pharmaceutical Announces Submissions In Europe And U.S. For Single-Tablet Regimen Of Dolutegravir Plus Rilpivirine - The First Two-Drug HIV Maintenance Treatment 6/2/2017
Merck & Co. (MRK) Release: With Nearly Three Years Of Follow-Up, KEYTRUDA (Pembrolizumab) Data Demonstrated Improved Survival Benefit Compared To Ipilimumab In Advanced Melanoma 6/2/2017
AstraZeneca PLC (AZN) Release: Lynparza (Olaparib) Maintenance Treatment Offers Sustained Quality Of Life Alongside Improved Progression-Free Survival In Women With BRCA-Mutated Ovarian Cancer 6/2/2017
Progenics (PGNX) Announces The Presentation Of Data From Two Automated Bone Scan Index Studies At The 2017 ASCO Annual Meeting 6/2/2017
Eight Presentations At ASM Microbe Include Late Breaker From Cempra (CEMP)’s Phase III Fusidic Acid Study And Solithromycin Data On Gonorrhea And Otitis Media 6/2/2017
Nabriva To Present Data At ASM Microbe Supporting Ongoing Phase III Clinical Development Program For Lefamulin 6/2/2017
AstraZeneca PLC (AZN) Release: Lynparza (olaparib) Maintenance Treatment Offers Sustained Quality Of Life Alongside Improved Progression-Free Survival In Women With BRCA-Mutated Ovarian Cancer 6/2/2017
Novartis AG (NVS) Presents Updated Data That Reinforce The Efficacy And Safety Of Kisqali (Ribociclib) Plus Letrozole As A First-Line Option For HR+/HER2- Advanced Or Metastatic Breast Cancer 6/2/2017
Neurocrine (NBIX) Announces Presentations Related To INGREZZA (Valbenazine) Capsules At The 21st International Congress Of Parkinson's Disease And Movement Disorders 6/2/2017
GENFIT (ALGFT): Positive Outcome From The 1-Year Pre-Planned Safety Review By The DSMB, In RESOLVE-IT Phase III Clinical Trial With Elafibranor 6/1/2017
GENFIT (ALGFT): Positive Outcome From The 1-Year Pre-Planned Safety Review By The DSMB, In RESOLVE-IT Phase III Clinical Trial With Elafibranor 6/1/2017
A Look at Gilead (GILD)'s Possible New Drug Strategy 6/1/2017
Eleven Bio (EBIO) Announces Data And Safety Monitoring Board (DSMB) Recommendation To Continue Phase III Registration Trial With Vicinium In Non-Muscle Invasive Bladder Cancer Based On Review Of Safety And Efficacy Data 6/1/2017
Jazz Pharma (JAZZ) Announces FDA Acceptance Of NDA For VYXEOS (CPX-351), An Investigational Treatment For Acute Myeloid Leukemia, With Priority Review Status 6/1/2017
Celgene (CELG) And Acceleron Pharma Complete Target Enrollment In The MEDALIST And BELIEVE Phase III Studies Of Luspatercept In Myelodysplastic Syndromes And Beta-Thalassemia 6/1/2017
vTv Therapeutics (VTVT) Completes Enrollment Of Part B Of Pivotal Phase III STEADFAST Trial Evaluating Azeliragon For The Treatment Of Patients With Mild Alzheimer’s Disease 6/1/2017
CytoDyn (CYDY) To Present An Update On Its PRO 140 Pivotal Phase IIb/III Study In Treatment-Experienced HIV-1 Patients At ASM Microbe 2017 6/1/2017
XBiotech (XBIT) Presents Phase III Findings For Its Antibody Therapy For Colorectal Cancer At The 2017 ASCO Meeting 6/1/2017
Shionogi Release: Further Evidence Supports Cefiderocol Activity Against MDR Gram-Negative Pathogens: Data Presented At The American Society For Microbiology Microbe (ASM) Meeting 6/1/2017
Sylentis Initiates A Phase III Study For The Treatment Of Dry Eye Syndrome 6/1/2017
BioPharm Executive: Here's What to Look For at ASCO 5/31/2017
Alnylam (ALNY) Jumps After the FDA Bestows Givosiran With Breakthrough Tag 5/31/2017
Anika Therapeutics (ANIK) Announces Data Presentation And Symposium On CINGAL At 2017 EFORT Annual Congress 5/31/2017
Sexual Function Improves In First-Line Patients Given Fexapotide Treatment In Nymox (NYMX) U.S. BPH Long-Term Clinical Trials 5/31/2017
Proove Biosciences Release: 90% Of Patients Achieve 40% Pain Reduction Within 60-Days In Large Precision Medicine Clinical Trial 5/31/2017
Eli Lilly (LLY)'s Cyramza Hits Goals in Phase III Bladder Cancer Study But Will Need to Wait for Overall Survival Data Due Mid-2018 5/31/2017
Teva (TEVA) Announces Positive Results For Phase III Study Of Fremanezumab For The Prevention Of Chronic Migraine 5/31/2017
TaiGen Biotechnology Announces Submission Of New Drug Application For Taigexyn Intravenous Formulation To The China Food And Drug Administration 5/30/2017
Lysogene Completes Enrollment In First International Pivotal Observational Study In MPS IIIA 5/30/2017



//-->